XLO

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

Xilio Therapeutics announces initiation of Phase 2 trial for Efarindodekin Alfa (XTX301), a tumor-activated IL-12, and achievement of $17.5 million development milestone under exclusive license agreement with GileadSep 9, 2025
Xilio Therapeutics updates Phase 2 data for Vilastobart in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancerJun 2, 2025